AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12148574
Drug: Ifosfamide by
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide by a 24-hour infusion on day 1
Trial: 12148574
Drug: Ifosfamide by
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide by a 3-hour infusion on days 1-4
Trial: 8307444
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg or 40 mg) for 5.7 weeks
Trial: 8307444
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prior antisecretory treatment)
Trial: 8307444
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg or 40 mg)
Trial: 6402051
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose (D5W) infusion
Trial: 18552701
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (Group B, n = 113)
Trial: 15776337
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group restricted to daily activities
Trial: 7782057
Drug: Purified urinary
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified urinary follicle‐stimulating hormone (uFSH‐HP; Metrodin HP®) in standard IVF
Trial: 7782057
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pure FSH and human menopausal gonadotrophin (hMG; Pergonal®) in standard IVF
Trial: 31442498
Drug: Optimal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal therapy (predicted)
Trial: 31442498
Drug: Actual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual therapy received
Trial: 24507657
Drug: TRO40303 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRO40303 (0.5 to 13 mg/kg)
Trial: 20676646
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate injection (SH)
Trial: 20676646
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy modalities (PTM)
Trial: 20179559
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.2 mg/kg)
Trial: 17331930
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL 6% hydroxyethyl starch (HES)
Trial: 17331930
Drug: 1500 mL
RxNorm normalized name: Bag/Pump Set 1500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mL lactated Ringer's (LR)
Trial: 7846196
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg IV as a 3-min infusion
Trial: 7846196
Drug: Zolpidem 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 20 mg orally
Trial: 7846196
Drug: Zolpidem 5
RxNorm normalized name: zolpidem 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 5 mg IV
Trial: 7846196
Drug: Zolpidem 5
RxNorm normalized name: zolpidem 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 5 mg orally
Trial: 1204500
Drug: Attenuated influenza-A-virus
RxNorm normalized name: influenza A virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated influenza-A-virus strain 'Alice' (H3N2), given intransally in drops (10(7,2) ID50 per dose), twice seven days apart
Trial: 1204500
Drug: Inactivated virus
RxNorm normalized name: covid-19, inactivated virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated virus vaccine
Trial: 28301620
Drug: CeraVe Itch
RxNorm normalized name: CeraVe itch Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CeraVe Itch Relief Lotion and Cream (1% pramoxine hydroxide)
Trial: 28301620
Drug: CeraVe Itch
RxNorm normalized name: CeraVe itch Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CeraVe Itch Relief Cream (1% pramoxine hydrochloride)
Trial: 28301620
Drug: CeraVe Itch
RxNorm normalized name: CeraVe itch Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CeraVe Itch Relief Cream (1% pramoxine hydrochloride) used daily over 6 days
Trial: 23329885
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 2.4 grams daily
Trial: 16397287
Drug: Sirolimus tablet
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus tablet
Trial: 16397287
Drug: Sirolimus solution
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus solution
Trial: 9170048
Drug: Breath-holding after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath-holding after O2 administration
Trial: 3536677
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole 500 mg eight hourly (19 patients)
Trial: 3536677
Drug: Identical intravenous
RxNorm normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical intravenous placebo (20 patients)
Trial: 3536677
Drug: Identical intravenous
RxNorm normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical intravenous placebo
Trial: 27097575
Drug: Budesonide suspension
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide suspension
Trial: 27097575
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no regular inhalation of corticosteroid)
Trial: 8594515
Drug: Brovincamine fumarate
RxNorm normalized name: vincamine
DrugBank: Vincamine (DB13374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brovincamine fumarate (20 mg 3 times daily)
Trial: 18707726
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 times daily)
Trial: 6961759
Drug: Labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200 mg daily
Trial: 3907824
Drug: Metoclopramide 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 60 mg
Trial: 3907824
Drug: Metoclopramide 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 120 mg
Trial: 29850782
Drug: Valsartan/Amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine combination therapy (80/5 mg) for 16 weeks
Trial: 22789773
Drug: Video-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-based therapy at home for patients with stroke (3 months duration)
Trial: 22789773
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (weekly outpatient therapy sessions)
Trial: 3354802
Drug: Caudal injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal injection of 1 ml/kg bupivacaine 0.25%
Trial: 3354802
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration of 0.5 ml/kg bupivacaine 0.25%
Trial: 27486141
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24-48 IU/day)
Trial: 25136015
Drug: GSK1322322 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 at 1,500 mg b.i.d.
Trial: 25136015
Drug: Linezolid at
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid at 600 mg b.i.d.
Trial: 23174463
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy group (IPT-G)
Trial: 18452826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PSA with other markers or tests
Trial: 11866009
Drug: Nacystelyn (NAL)
RxNorm normalized name: Nacystelyn
DrugBank: Nacystelyn (DB17839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nacystelyn (NAL) 24 mg (12 puffs)
Trial: 11866009
Drug: Nacystelyn (NAL)
RxNorm normalized name: Nacystelyn
DrugBank: Nacystelyn (DB17839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nacystelyn (NAL) (4 mg to 16 mg, varying doses)
Trial: 8829889
Drug: Aceclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac (100 mg b.i.d.)
Trial: 10791619
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg t.i.d.)
Trial: 326265
Drug: Ditenate Tetra
RxNorm normalized name: tetracycline hydrochloride Oral Capsule [Tetra 500]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ditenate Tetra (combination of tetracycline, theophylline, doxylamine succinate, etafedrine, phenylephrine, and guaifenesine)
Trial: 29275919
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg melatonin (2 melatonin capsules, 5 mg each)
Trial: 20007932
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment (n = 178)
Trial: 20007932
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (n = 181)
Trial: 12152002
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Trial: 12152002
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Trial: 12152002
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 30 mg lansoprazole and 750 mg amoxicillin for 7 days without clarithromycin
Trial: 12152002
Drug: H pylori-positive
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori-positive patients given 400 mg/day clarithromycin
Trial: 12152002
Drug: H pylori-positive
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori-positive patients given 800 mg/day clarithromycin
Trial: 12152002
Drug: Both patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both patient groups (200 mg and 400 mg clarithromycin)
Trial: 10527181
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d of risedronate
Trial: 11185630
Drug: hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide 25 mg
Trial: 27599667
Drug: amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 10 mg
Trial: 2185158
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g daily for 5 days
Trial: 2185158
Drug: Oral penicillin
RxNorm normalized name: penicillin G Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral penicillin 1 million units 3 times daily for 12 days
Trial: 1829514
Drug: Oral penicillin
RxNorm normalized name: penicillin G Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral penicillin
Trial: 31531960
Drug: Immediate-release prednisolone
RxNorm normalized name: prednisolone Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release prednisolone (IR)
Trial: 28243723
Drug: PBM-LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM-LED therapy
Trial: 26209223
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT) continuation
Trial: 26209223
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT) discontinuation
Trial: 25502511
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta 1 mg/kg biweekly
Trial: 19954719
Drug: Tacrolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (3 mg/day, 0.04 - 0.075 mg/kg)
Trial: 17578464
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 2 microg/kg
Trial: 15187493
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril and candesartan
Trial: 22011217
Drug: EE/DRSP (ethinyl-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/DRSP (ethinyl-estradiol 30 mcg/drospirenone 3 mg)
Trial: 22011217
Drug: EE/CMA (ethinyl-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/CMA (ethinyl-estradiol 30 mcg/chlormadinone acetate 2 mg)
Trial: 21056810
Drug: C(et) of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C(et) of remifentanil 0.5 ng/mL
Trial: 21056810
Drug: C(et) of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C(et) of remifentanil 1 ng/mL
Trial: 21056810
Drug: C(et) of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C(et) of remifentanil 1.5 ng/mL
Trial: 17985581
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium group 1 (Mg1 G) - 50 mg kg(‐1) preoperatively followed by 8 mg kg(‐1) h(‐1) infusion
Trial: 17985581
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium group 2 (Mg2 G) - 50 mg kg(‐1) preoperatively followed by 16 mg kg(‐1) h(‐1) infusion
Trial: 17985581
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - isotonic solution
Trial: 15659503
Drug: Attenuated-dose (AD)
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated-dose (AD) regimen: cisplatin 25 mg/m² on days 1 and 2, etoposide 60 mg/m² on days 1, 2, and 3 every 3 weeks.
Trial: 15659503
Drug: Full-dose (FD)
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose (FD) regimen: cisplatin 40 mg/m² on days 1 and 2, etoposide 100 mg/m² on days 1, 2, and 3 every 3 weeks, plus lenograstim 5 mg/kg days 5 through 12, every 3 weeks.
Trial: 12477996
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (160 mg twice per day oral suspension)
Trial: 2317419
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction with isoflurane and rectal thiopentone premedication
Trial: 2317419
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction with isoflurane without premedication
Trial: 2317419
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction with halothane and rectal thiopentone premedication
Trial: 2317419
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction with halothane without premedication
Trial: 6773613
Drug: Propranolol 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 480 mg/day
Trial: 6773613
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propranolol and nifedipine
Trial: 28285571
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment using visual imagery under conditions of rote repetition and spaced retrieval
Trial: 28285571
Drug: No-treatment attention
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment attention control
Trial: 28285571
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment using visual imagery
Trial: 26402079
Drug: 2.3 g
RxNorm normalized name: Urea 2.3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.3 g ω3 FA daily for 6 months
Trial: 23733403
Drug: Extended-release memantine
RxNorm normalized name: memantine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release memantine (28 mg, once daily)
Trial: 19515737
Drug: Lignan supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignan supplements
Trial: 17088453
Drug: Acipimox (inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (inhibitor of lipolysis)
Trial: 15474700
Drug: Picotamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (600 mg bid)
Trial: 15474700
Drug: Aspirin (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (320 mg od)
Trial: 11197402
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at 20 ppm
Trial: 9232132
Drug: Alfentanil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously)
Trial: 9232132
Drug: Alfentanil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with rifampin induction
Trial: 9232132
Drug: Alfentanil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with troleandomycin inhibition
Trial: 8007760
Drug: Cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine hydrochloride (10 mg unit doses, intranasally)
Trial: 31229240
Drug: Pexidartinib (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexidartinib (1000 mg per day for 2 weeks, then 800 mg per day for 22 weeks)
Trial: 21971662
Drug: L‐Ala‐Gln (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐Ala‐Gln (20% solution, 0.5g/Kg, adding saline to complete 100ml)
Trial: 21971662
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (100 ml, delivered intravenously over 3 hours)
Trial: 17197214
Drug: ketamine/remifentanil (KET/REMI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine/remifentanil (KET/REMI) at low REMI target concentration (1ng/ml)
Trial: 17197214
Drug: placebo/remifentanil (P/REMI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo/remifentanil (P/REMI) at 2ng/ml target concentration
Trial: 17197214
Drug: ketamine/remifentanil (KET/REMI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine/remifentanil (KET/REMI) at 2ng/ml target concentration
Trial: 15715026
Drug: Cognitive‐Behavioral Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Treatment (CBT Group)
Trial: 11597824
Drug: Paroxetine 20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20‐40 mg
Trial: 11597824
Drug: Paroxetine 20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20‐40 mg with pindolol
Trial: 9150858
Drug: S‐naproxen betainate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐naproxen betainate sodium salt monohydrate (naproxen‐betaNa), 575 mg capsule containing 342 mg of S‐naproxen
Trial: 9150858
Drug: Sodium salt
RxNorm normalized name: Hepes Sodium Salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium salt of S‐naproxen (reference), two 275 mg tablets containing 502 mg of S‐naproxen
Trial: 8205295
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 or 5.0 mg twice daily)
Trial: 3548930
Drug: Ticarcillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin/clavulanic acid (3 g ticarcillin and 100 mg clavulanic acid every 8 hours)
Trial: 3548930
Drug: Metronidazole/netilmicin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole/netilmicin (500 mg metronidazole and 80 mg netilmicin every 8 hours)
Trial: 25326180
Drug: Standard non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard non-surgical therapy + sham treatments (Control Group)